MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company, reported significant Q2 2025 milestones and financial results. The company achieved a notable breakthrough with a durable complete remission in metastatic testicular cancer using their agenT-797 therapy, published in Nature's Oncogene.
MiNK secured substantial funding through two non-dilutive grants from the Department of Defense for GvHD research and raised $13 million through equity sales post-Q2, extending their cash runway beyond mid-2026. The company reported a Q2 2025 net loss of $4.2 million ($1.06 per share) compared to $2.7 million in Q2 2024, with cash and equivalents of $1.6 million at quarter-end.
MiNK Therapeutics (NASDAQ: INKT), una societ脿 biofarmaceutica in fase clinica, ha comunicato importanti traguardi e risultati finanziari del secondo trimestre 2025. L'azienda ha ottenuto un risultato rilevante con una remissione completa durevole in un carcinoma testicolare metastatico grazie alla terapia agenT-797, pubblicata sulla rivista Oncogene (Nature).
MiNK ha ottenuto finanziamenti significativi tramite due sovvenzioni non dilutive dal Department of Defense per la ricerca sulla GvHD e ha raccolto 13 milioni di dollari tramite vendite di azioni dopo la chiusura del trimestre, estendendo la propria liquidit脿 oltre la met脿 del 2026. La societ脿 ha riportato una perdita netta nel Q2 2025 di 4,2 milioni di dollari (1,06 $ per azione) rispetto a 2,7 milioni nel Q2 2024, con disponibilit脿 liquide di 1,6 milioni di dollari a fine trimestre.
MiNK Therapeutics (NASDAQ: INKT), una compa帽铆a biofarmac茅utica en fase cl铆nica, inform贸 hitos importantes y resultados financieros del segundo trimestre de 2025. La empresa logr贸 un avance notable con una remisi贸n completa durable en c谩ncer testicular metast谩sico mediante su terapia agenT-797, publicada en la revista Oncogene (Nature).
MiNK asegur贸 financiaci贸n considerable a trav茅s de dos subvenciones no dilutivas del Department of Defense para la investigaci贸n de la GvHD y recaud贸 13 millones de d贸lares mediante ventas de acciones tras el cierre del trimestre, extendiendo su liquidez m谩s all谩 de mediados de 2026. La compa帽铆a registr贸 una p茅rdida neta en el Q2 2025 de 4,2 millones de d贸lares (1,06 $ por acci贸n) frente a 2,7 millones en el Q2 2024, con efectivo y equivalentes por 1,6 millones de d贸lares al final del trimestre.
MiNK Therapeutics (NASDAQ: INKT), 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓臧� 2025雲� 2攵勱赴 欤检殧 靹标臣 氚� 鞛 瓴瓣臣毳� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� agenT-797 旃橂搿� 鞝勳澊靹� 瓿犿櫂鞎旍棎靹� 歆�靻嶌爜 鞕勳爠 甏�頃�毳� 雼劚頄堨溂氅� 頃措嫻 瓴瓣臣電� Nature 瓿勳棿 頃欖垹歆� Oncogene鞐� 瓴岇灛霅橃棃鞀惦媹雼�.
MiNK電� GvHD(鞚挫嫕韼鸽寑靾欖＜氤�) 鞐瓣惮毳� 鞙勴暣 氙戈淡 甑癌攵�(Department of Defense)搿滊秬韯� 牍勴潿靹濎劚 氤挫“旮� 霊� 瓯�鞚� 頇曤炒頄堨溂氅�, 攵勱赴 膦呺 頉� 欤检嫕 氚滍枆鞚� 韱淀暣 1,300毵� 雼煬毳� 臁半嫭頃� 順勱笀 鞙犽彊靹膘潉 2026雲� 欷戨皹 鞚错泟旯岇 鞐办灔頄堨姷雼堧嫟. 須岇偓電� 2025雲� 2攵勱赴 靾滌啇鞁れ澊 420毵� 雼煬(欤茧嫻 1.06雼煬)搿�, 2024雲� 2攵勱赴 270毵� 雼煬鞕� 牍勱祼霅橂┌ 攵勱赴 毵� 順勱笀 氚� 順勱笀靹� 鞛愳偘鞚� 160毵� 雼煬鞓赌鞀惦媹雼�.
MiNK Therapeutics (NASDAQ: INKT), une soci茅t茅 biopharmaceutique en phase clinique, a annonc茅 des jalons importants et ses r茅sultats financiers du deuxi猫me trimestre 2025. La soci茅t茅 a obtenu une avanc茅e notable avec une r茅mission compl猫te durable d'un cancer testiculaire m茅tastatique gr芒ce 脿 sa th茅rapie agenT-797, publi茅e dans la revue Oncogene (Nature).
MiNK a obtenu des financements substantiels via deux subventions non dilutives du Department of Defense pour la recherche sur la GvHD et a lev茅 13 millions de dollars par ventes d'actions apr猫s le T2, prolongeant sa tr茅sorerie au-del脿 de mi-2026. La soci茅t茅 a d茅clar茅 une perte nette au T2 2025 de 4,2 millions de dollars (1,06 $ par action) contre 2,7 millions au T2 2024, avec des liquidit茅s et 茅quivalents de 1,6 million de dollars 脿 la cl么ture du trimestre.
MiNK Therapeutics (NASDAQ: INKT), ein biopharmazeutisches Unternehmen in der klinischen Phase, berichtete 眉ber bedeutende Meilensteine und Finanzkennzahlen f眉r das zweite Quartal 2025. Das Unternehmen erzielte einen wichtigen Durchbruch mit einer dauerhaften kompletten Remission bei metastasiertem Hodenkrebs durch seine agenT-797-Therapie, ver枚ffentlicht in der Fachzeitschrift Oncogene (Nature).
MiNK sicherte sich erhebliche Mittel durch zwei nicht verw盲ssernde Zusch眉sse des Department of Defense zur GvHD-Forschung und nahm 13 Millionen US-Dollar durch Aktienverk盲ufe nach dem zweiten Quartal ein, wodurch die Liquidit盲t bis 眉ber Mitte 2026 hinaus verl盲ngert wurde. Das Unternehmen meldete im Q2 2025 einen Nettoverlust von 4,2 Millionen US-Dollar (1,06 $ je Aktie) gegen眉ber 2,7 Millionen im Q2 2024, mit liquiden Mitteln von 1,6 Millionen US-Dollar zum Quartalsende.
- Landmark case of complete remission in metastatic testicular cancer patient using agenT-797
- Secured Department of Defense STTR grant for GvHD research
- Additional clinical grant awarded for GvHD trial initiation
- Raised $13 million post-Q2, extending cash runway beyond mid-2026
- Reduced cash burn with Q2 2025 operating cash use of $1.57M vs $2.29M in Q2 2024
- Net loss increased to $4.2M in Q2 2025 from $2.7M in Q2 2024
- Low cash position of $1.6M at Q2 end before additional funding
Insights
MiNK extended cash runway to mid-2026 with $13M raised, secured two non-dilutive grants for GvHD program, and reported promising clinical data.
MiNK Therapeutics has significantly improved its financial position, extending its cash runway beyond mid-2026 through a
The company's Q2 net loss widened to
On the clinical front, MiNK's publication in Nature's Oncogene featuring a patient with treatment-refractory metastatic testicular cancer achieving complete remission following a single infusion of agenT-797 represents a potentially significant proof-of-concept for their invariant natural killer T (iNKT) cell platform. While a single case study doesn't prove broad efficacy, durable complete remissions in heavily pretreated patients merit attention.
The company is now expanding beyond oncology with their GvHD program, supported by Department of Defense funding and an additional clinical grant. This diversification could reduce risk while potentially accelerating the validation of their platform technology in a new therapeutic area. Meanwhile, their Phase 2 trial in second-line gastric cancer continues with additional readouts expected this year, which will provide more substantive evidence of efficacy.
- Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric Cancer
- Department of Defense STTR Grant to advance INKTs in GVHD announced; program advancing
- New clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs.
鈥淚n Q2, we demonstrated the power of our platform with high impact clinical results, publication of key clinical findings, and competitive, non-dilutive, federal funding,鈥� said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. 鈥淪ince quarter-end, we further strengthened our financial position that extends our runway beyond mid-2026. With our cash position, coupled with two separate non-dilutive grants for the clinical advancement of allo-INKTs in GvHD 鈥� we can achieve substantial clinical program advancements.鈥�
Highlights from Q2 2025
- Durable Complete Remission in Metastatic Testicular Cancer: publication of a landmark case of a patient with treatment-refractory metastatic testicular cancer who achieved a durable complete remission following a single infusion of agenT-797 (allo-INKTs) in combination with checkpoint blockade. The patient remains disease-free more than two years post-treatment.
- Strengthened Balance Sheet: Increased cash reserves extending runway beyond mid-2026 to advance clinical programs.
- Department of Defense STTR Grant Awarded for GvHD: Competitive DOD STTR grant awarded to advance development of iNKTs for graft-versus-host disease (GvHD) prevention and treatment; program launched.
- NEW Clinical Grant Awarded for GvHD: Additional clinical competitive grant awarded to initiate a first-in-human clinical trial of iNKTs in GvHD, with trial initiation targeted in 2H2025.
- Progress in Phase 2 Gastric Cancer Study: Phase 2 trial of agenT-797 in second-line gastric cancer anticipated additional clinical readouts in 2025.
- Peer-Reviewed Review of iNKT Cell Therapy: A featured MiNK鈥檚 platform, highlighting iNKT cells鈥� can remodel the tumor microenvironment and overcome therapeutic resistance, showcasing CAR-iNKTs, such as MiNK-215 as a next-generation solution for solid tumors.
Financial Highlights
- Cash Position: MiNK ended Q2 2025 with approximately
$1.6 million in cash and cash equivalents and subsequently raised$13 million through equity sales, providing expected runway into mid-2026.听听 - Net Loss: Net loss for Q2 2025 was
$4.2 million , or$1.06 per share, compared to$2.7 million , or$0.73 per share for Q2 2024. For the first half of 2025, net loss was$7 million , or$1.76 per share compared to$6.5 million or$1.82 per share for the first half of 2024. Current period results reflect ongoing activity supporting our agent-797 programs and non-cash expenses including the impact of repricing of certain equity awards.
| Summary Consolidated Financial Information | |||||||||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Condensed Consolidated Balance Sheet Data | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| 听 | June 30, 2025 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Cash and cash equivalents | $ | 1,682 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||
| Cash raised since quarter end | 听 | 13,012 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Other Financial Information | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| 听 | Three months ended June 30, | 听 | Six months ended June 30, | ||||||||||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Cash used in operations | $ | 1,569 | 听 | 听 | $ | 2,291 | 听 | 听 | $ | 2,910 | 听 | 听 | $ | 4,833 | 听 |
| Non-cash expenses | 听 | 1,501 | 听 | 听 | 听 | 491 | 听 | 听 | 听 | 2,336 | 听 | 听 | 听 | 1,141 | 听 |
| Net loss | 听 | 4,237 | 听 | 听 | 听 | 2,702 | 听 | 听 | 听 | 7,004 | 听 | 听 | 听 | 6,515 | 听 |
| Net loss per share | 听 | 1.06 | 听 | 听 | 听 | 0.73 | 听 | 听 | 听 | 1.76 | 听 | 听 | 听 | 1.82 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
Conference Call and Webcast Information
MiNK will host a conference call and webcast on August 14, 2025, at 8:30 a.m. ET.
To access the live call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (International) and reference conference ID 1149380.
A live webcast and replay will be available in the Events & Presentations section of MiNK鈥檚 investor website at .
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370 |
Media Contact
781-674-4422 |
FAQ
What were MiNK Therapeutics' (INKT) key clinical achievements in Q2 2025?
How much funding did MiNK Therapeutics (INKT) secure in Q2 2025?
What was MiNK Therapeutics' (INKT) financial performance in Q2 2025?
What are MiNK Therapeutics' (INKT) plans for GvHD clinical trials?
What is the cash runway outlook for MiNK Therapeutics (INKT)?
